Opus Genetics Inc. (IRD) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, IRD scores 23 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 1 of 20, reflecting ROIC of -35% and FCF yield of -11.61%; this is the weakest pillar and indicates the business is currently consuming rather than generating cash relative to its market value. The Whale 13F Flow pillar scores 4 of 20, pointing to limited institutional accumulation and options positioning support. The Insider Conviction pillar scores 3 of 20, reflecting weak SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 7 of 20 with a Beta of 1.0, meaning the stock tracks overall market movement without a defensive or amplifying profile per the rating. The Forensic Balance Sheet pillar scores 8 of 20, combining an Altman Z-Score of 0.2 (a level the rating treats as distress-adjacent), a Piotroski F-Score of 5 of 9, and a Debt/Equity ratio of 0.07. For a prospective investor evaluating the stock today, the rating's implications are that upside drivers would need to come from pipeline or regulatory events rather than current cash generation, that valuation rests on future outcomes not visible in present earnings, and that the forensic indicators argue for heightened caution on balance-sheet durability. Trading at $3.65 within a 52-week range of $1.7 to $7.07, the stock sits in the lower-middle portion of its range.

Per the SEC financials and market data, gross margin is 0%, operating margin is -60%, and net margin is -60%. ROIC is -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 5 of 9, both per the Roarable RQD rating. Debt/Equity is 0.07 and reported debt was $1.1M at FY 2025 against cash of $45.1M.

• Yahoo! Finance Canada and Seeking Alpha items cover market action and an Euretina 2026 presentation, rated YELLOW under the MARKET WIRE category.
• Moomoo and Investing.com items cover options chain data and a reported president sale of $117,364 in IRD stock, rated YELLOW.
• A Yahoo Finance item discusses a possible FDA decision on MR-141 and its relevance to Viatris (VTRS) and IRD, rated YELLOW.
• A Stocktwits item on October FDA decision watch names IRD among potential catalysts, rated RED under the RISK WATCH category, the only red-flagged item in the set.
• Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE, with no butterfly links and no proprietary signals recorded.

• What are the specific product candidates, development stages, and regulatory timelines behind the FDA-related catalysts referenced in the news set?
• What drove the year-over-year revenue change from $11.0M in FY 2024 to $14.2M in FY 2025, and what portion is recurring versus one-time?
• What is the cash runway given FY 2025 FCF of $-35.3M against cash of $45.1M, and are there financing or dilution plans?
• Who are the counterparties, licensors, or partners that determine the company's revenue base, and are there any supply-chain dependencies?
• What do insider sales and institutional ownership levels look like in full detail, since the holder data is not provided?